Deslocamento linear longitudinal do ventrículo esquerdo comparado ao strain longitudinal global por ressonância magnética cardiovascular / Left ventricular longitudinal linear displacement versus global longitudinal strain on cardiovascular magnetic resonance

Introdução: A função sistodiastólica do ventrículo esquerdo é prognóstica nas doenças cardiovasculares e pode ser avaliada por strain longitudinal global por meio de ecocardiografia e de ressonância magnética cardíaca. O strain longitudinal global pela ressonância magnética cardíaca exige a utilização de software de alto custo. O deslocamento linear longitudinal do ventrículo esquerdo pode ser uma alternativa simples e barata ao strain longitudinal global, porém eles não foram ainda comparados sistematicamente. Objetivo: Comparar o deslocamento linear longitudinal com o strain longitudinal global e fração de ejeção do ventrículo esquerdo em valvopatas aórticos e controles. Métodos: Incluímos 44 participantes (26 valvopatas aórticos/19 controles). O strain longitudinal global utilizou software específico (Circle Cardiovascular Imaging 42) e o deslocamento linear longitudinal apenas medidas lineares de distância entre a base e o ápex do ventrículo esquerdo, gerando deslocamento máximo, velocidade máxima no início da diástole, velocidade na diástase e a relação entre velocidade na diástase e velocidade máxima no início da diástole. Resultados: Deslocamento máximo e velocidade máxima no início da diástole correlacionaram-se com strain longitudinal global (r=0,69 e r=0,65 respectivamente) e com a fração de ejeção do ventrículo esquerdo (r=0,47 e r=0,57, p<0,001 para ambos). Deslocamento máximo e velocidade máxima no início da diástole apresentaram área sob a curva Característica de Operação do Receptor de 0,88 e 0,91 e, no melhor ponto de corte (-0,13 e 0,66), sensibilidade de 72,43% e 57,14% e especificidade 80,65% e 87,10%, respectivamente, quando comparados ao strain longitudinal global. Utilizando a fração de ejeção do ventrículo esquerdo como referência, foram obtidos 0,70 e 0,82, e, no melhor ponto de corte (-0,11 e 0,61), sensibilidade de 75,00% e 50,00% e especificidade 72,97% e 78,38%, respectivamente. Conclusão: O deslocamento linear longitudinal foi semelhante ao strain longitudinal global. O deslocamento máximo derivado do deslocamento linear longitudinal foi o melhor parâmetro na sístole, enquanto a velocidade máxima no início da diástole foi o melhor na diástole, o que possibilita a avaliação da função diastólica pela ressonância magnética cardíaca na rotina clínica de forma rápida e sem custo adicional.(AU)

Background: Left ventricular (LV) systolic diastolic function is prognostic in cardiovascular diseases and can be assessed via global longitudinal strain (GLS) on echocardiography and cardiac magnetic resonance (CMR). However, GLS by CMR requires the use of expensive software. Longitudinal linear displacement (LLD) may be a simple and inexpensive alternative to GLS, but the two have not been systematically compared. Objective: To compare LLD with GLS and LV ejection fraction (LVEF) in aortic valve disease patients and controls. Methods: We included 44 participants (26 with aortic valve disease, 19 controls). GLS was determined using CVI42 software (Circle Cardiovascular Imaging), while the LLD linear measurements of the distance between the base/apex of the LV included maximum displacement (MD), maximum velocity in early diastole (MVED), atrioventricular junction velocity in diastasis (VDS), and VDS/MVED ratio. Results: DM and MVED were correlated with GLS (r=0.69 and r=0.65, respectively) and LVEF (r=0.47 and r=0.57, p<0.001 for both). DM and MVED showed areas under the receiver operating characteristic curve (AUC) of 0.88 and 0.91, and at the best cut-off point (-0.13 and 0.66), sensitivities of 72.43% and 57.14% and specificities of 80.65% and 87.10%, respectively, compared to GLS. Using LVEF as a reference, we obtained AUC of 0.70 and 0.82, and at the best cut-off point (-0.11 and 0.61), sensitivities of 75.00% and 50.00% and specificities of 72.97% and 78.38%, respectively. Conclusion: LLD demonstrated similar performance to that of GLS. MD derived from LLD was the best parameter during systole, while MVED was the best during diastole. Our findings demonstrate the routine, quick, and inexpensive assessment of diastolic function on CMR.(AU)

Síndrome de Heyde: Estratégias Terapêuticas e Seguimento de Longo Prazo / Heyde's Syndrome: Therapeutic Strategies and Long-Term Follow-Up

Resumo Fundamentos A síndrome de Heyde é a associação de estenose aórtica importante com episódio de sangramento gastrointestinal por lesões angiodisplásicas. Pouco é conhecido sobre os fatores associados a novos sangramentos e desfechos em longo prazo. Além disso, a maioria dos dados é restrita a relatos de casos e pequenas séries. Objetivo Avaliar o perfil clínico, laboratorial e ecocardiográfico de pacientes com síndrome de Heyde submetidos a intervenção valvar ou tratamento medicamentoso. Métodos Coorte prospectiva de 24 pacientes consecutivos entre 2005 e 2018. Foram avaliados dados clínicos, laboratoriais, ecocardiográficos e relacionados à intervenção valvar e a desfechos após o diagnóstico. Valor de p<0,05 foi considerado estatisticamente significante. Resultados Metade dos 24 pacientes apresentou sangramento com necessidade de transfusão sanguínea na admissão. Angiodisplasias foram encontradas mais frequentemente no cólon ascendente (62%). Intervenção valvar (cirúrgica ou transcateter) foi realizada em 70,8% dos pacientes, e 29,2% foram mantidos em tratamento clínico. Novos episódios de sangramento ocorreram em 25% dos casos, e não houve diferença entre os grupos clínico e intervenção (28,6 vs. 23,5%, p=1,00; respectivamente). A mortalidade no seguimento de 2 e 5 anos foi de 16% e 25%, sem diferença entre os grupos (log-rank p = 0,185 e 0,737, respectivamente). Conclusões Pacientes com síndrome de Heyde tiveram alta taxa de sangramento com necessidade de transfusão sanguínea na admissão, sugerindo ser uma doença grave e com risco elevado de mortalidade. Não encontramos diferenças entre os grupos submetidos ao tratamento clínico e à intervenção valvar em relação a taxas de ressangramento e mortalidade tardia.

Abstract Background Heyde's syndrome is the association of severe aortic stenosis with episodes of gastrointestinal bleeding due to angiodysplastic lesion. Little is known about the factors associated with new episodes of bleeding and long-term outcomes. Furthermore, most data are restricted to case reports and small case series. Objective To assess the clinical, laboratory and echocardiography profile of patients with Heyde's syndrome who underwent valve intervention or drug therapy. Methods Prospective cohort of 24 consecutive patients from 2005 to 2018. Clinical, laboratory and echocardiography data were assessed, as well as those related to valve intervention and outcomes after diagnosis. A P <0.05 was used to indicate statistical significance. Results Half of the 24 patients presented with bleeding requiring blood transfusion on admission. Angiodysplasias were more frequently found in the ascending colon (62%). Valve intervention (surgical or transcatheter) was performed in 70.8% of the patients, and 29.2% remained on drug therapy. News episodes of bleeding occurred in 25% of the cases, and there was no difference between clinical and intervention groups (28.6 vs 23.5%, p = 1.00; respectively). Mortality at 2-year and 5-year was 16% and 25%, with no difference between the groups (log-rank p = 0.185 and 0.737, respectively). Conclusions Patients with Heyde's syndrome had a high rate of bleeding requiring blood transfusion on admission, suggesting that it is a severe disease with high mortality risk. No difference was found between clinical and intervention group regarding the rate of rebleeding and late mortality.

A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: rationale and design of the RIVER trial

Background The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain. Design RIVER was an academic-led, multicenter, open-label, randomized, non-inferiority trial with blinded outcome adjudication that enrolled 1005 patients from 49 sites in Brazil. Patients with a bioprosthetic mitral valve and atrial fibrillation or flutter were randomly assigned (1:1) to rivaroxaban 20 mg once daily (15 mg in those with creatinine clearance <50 mL/min) or dose-adjusted warfarin (target international normalized ratio 2.0-30.); the follow-up period was 12 months. The primary outcome was a composite of all-cause mortality, stroke, transient ischemic attack, major bleeding, valve thrombosis, systemic embolism, or hospitalization for heart failure. Secondary outcomes included individual components of the primary composite outcome, bleeding events, and venous thromboembolism. Summary RIVER represents the largest trial specifically designed to assess the efficacy and safety of a direct oral anticoagulant in patients with bioprosthetic mitral valves and atrial fibrillation or flutter. The results of this trial can inform clinical practice and international guidelines.

Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve

BACKGROUND The effects of rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve remain uncertain. METHODS In this randomized trial, we compared rivaroxaban (20 mg once daily) with dose adjusted warfarin (target international normalized ratio, 2.0 to 3.0) in patients with atrial fibrillation and a bioprosthetic mitral valve. The primary outcome was a composite of death, major cardiovascular events (stroke, transient ischemic attack, systemic embolism, valve thrombosis, or hospitalization for heart failure), or major bleeding at 12 months. RESULTS A total of 1005 patients were enrolled at 49 sites in Brazil. A primary-outcome event occurred at a mean of 347.5 days in the rivaroxaban group and 340.1 days in the warfarin group (difference calculated as restricted mean survival time, 7.4 days; 95% confidence interval [CI], −1.4 to 16.3; P<0.001 for noninferiority). Death from cardiovascular causes or thromboembolic events occurred in 17 patients (3.4%) in the rivaroxaban group and in 26 (5.1%) in the warfarin group (hazard ratio, 0.65; 95% CI, 0.35 to 1.20). The incidence of stroke was 0.6% in the rivaroxaban group and 2.4% in the warfarin group (hazard ratio, 0.25; 95% CI, 0.07 to 0.88). Major bleeding occurred in 7 patients (1.4%) in the rivaroxaban group and in 13 (2.6%) in the warfarin group (hazard ratio, 0.54; 95% CI, 0.21 to 1.35). The frequency of other serious adverse events was similar in the two groups. CONCLUSIONS In patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months.

Longitudinal Shortening of the Left Ventricle by Cine-CMR for Assessment of Diastolic Function in Patients with Aortic Valve Disease / Encurtamento Longitudinal do Ventrículo Esquerdo por Cine-RMC para Avaliação da Função Diastólica em Pacientes com Doença Valvar Aórtica

Abstract Background: Diastolic dysfunction, commonly evaluated by echocardiography, is an important early finding in many cardiomyopathies. Cardiac magnetic resonance (CMR) often requires specialized sequences that extends the test time. Recently, feature-tracking imaging has been made available, but still requires expensive software and lacks clinical validation. Objective: To assess diastolic function in patients with aortic valve disease (AVD) and compare it with normal controls by evaluating left ventricular (LV) longitudinal displacement by CMR. Methods: We compared 26 AVD patients with 19 normal controls. Diastolic function was evaluated as LV longitudinal displacement in 4-chamber view cine-CMR images using steady state free precession (SSFP) sequence during the entire cardiac cycle with temporal resolution < 50 ms. The resulting plot of atrioventricular junction (AVJ) position versus time generated variables of AVJ motion. Significance level of p < 0.05 was used. Results: Maximum longitudinal displacement (0.12 vs. 0.17 cm), maximum velocity during early diastole (MVED, 0.6 vs. 1.4s-1), slope of the best-fit line of displacement in diastasis (VDS, 0.22 vs. 0.03s-1), and VDS/MVED ratio (0.35 vs. 0.02) were significantly reduced in AVD patients compared with controls, respectively. Aortic regurgitation showed significantly worse longitudinal LV shortening compared with aortic stenosis. Higher LV mass indicated worse diastolic dysfunction. Conclusions: A simple linear measurement detected significant differences on LV diastolic function between AVD patients and controls. LV mass was the only independent predictor of diastolic dysfunction in these patients. This method can help in the evaluation of diastolic dysfunction, improving cardiomyopathy detection by CMR, without prolonging exam time or depending on expensive software.

Resumo Fundamentos: A disfunção diastólica, comumente avaliada por ecocardiografia, é um importante achado precoce na maioria das cardiomiopatias. A ressonância magnética cardíaca (RMC) frequentemente requer sequências específicas que prolongam o tempo de exame. Recentemente, métodos de imagens com monitoramento de dados (feature-tracking) foram desenvolvidos, mas ainda requerem softwares caros e carecem de validação clínica. Objetivos: Avaliar a função diastólica em pacientes com doença valvar aórtica (DVA) e compará-la a controles normais pela medida do deslocamento longitudinal do ventrículo esquerdo (VE) por RMC. Métodos: Nós comparamos 26 pacientes com DVA com 19 controles normais. A função diastólica foi avaliada como uma medida do deslocamento longitudinal do VE nas imagens de cine-RMC no plano quatro câmaras usando a sequência steady state free precession (SSFP) durante todo o ciclo cardíaco com resolução temporal < 50 ms. O gráfico resultante da posição da junção atrioventricular versus tempo gerou variáveis de movimento da junção atrioventricular. Utilizamos nível de significância de p < 0,005. Resultados: Deslocamento longitudinal máximo (0,12 vs. 0,17 cm), velocidade máxima em início de diástole (0,6 vs. 1,4s-1), velocidade máxima na diástase (0,22 vs. 0,03s-1) e a razão entre a velocidade máxima na diástase e a velocidade máxima em diástole inicial (0,35 vs. 0,02) foram significativamente menores nos pacientes com DVA em comparação aos controles normais, respectivamente. Pacientes com insuficiência aórtica apresentaram medidas de encurtamento longitudinal do VE significativamente piores em comparação aqueles com estenose aórtica. O aumento da massa ventricular esquerda indicou pior disfunção diastólica. Conclusões: Esta simples medida linear detectou diferenças significativas na função diastólica do VE entre pacientes com DVA e controles normais. A massa ventricular esquerda foi o único preditor independente de disfunção diastólica nesses pacientes. Este método pode auxiliar na avaliação da disfunção diastólica, melhorando a detecção de cardiomiopatias por RMC sem prolongar o tempo de exame ou depender de caros softwares.

Thrombocytopenia after transcatheter valve-in-valve implantation: prognostic marker or mere finding?

Abstract Objective: To analyze the behavior of platelets after transcatheter valve-in-valve implantation for the treatment of degenerated bioprosthesis and how they correlate with adverse events upon follow-up. Methods: Retrospective analysis of 28 patients who received a valve-in-valve implant, 5 in aortic, 18 in mitral and 5 in tricuspid positions. Data were compared with 74 patients submitted to conventional redo valvular replacements during the same period, and both groups' platelet curves were analyzed. Statistical analysis was conducted using the IBM SPSS Statistics(r) 20 for Windows. Results: All patients in the valve-in-valve group developed thrombocytopenia, 25% presenting mild (<150.000/µL), 54% moderate (<100.000/µL) and 21% severe (<50.000/µL) thrombocytopenia. The platelet nadir was on the 4th postoperative day for aortic ViV, 2nd for mitral and 3rd for tricuspid patients, with the majority of patients recovering regular platelet count. However, the aortic subgroup comparison between valve-in-valve and conventional surgery showed a statistically significant difference from the 7th day onwards, where valve-in-valve patients had more severe and longer lasting thrombocytopenia. This, however, did not translate into a higher postoperative risk. In our study population, postoperative thrombocytopenia did not correlate with greater occurrence of adverse outcomes and only normal preoperative platelet count could significantly predict a postoperative drop >50%. Conclusion: Although thrombocytopenia is an extremely common finding after valve-in-valve procedures, the degree of platelet count drop did not correlate with greater incidence of postoperative adverse outcomes in our study population.